Sarepta Therapeutics Inc.’s bid for the full Federal Circuit’s review of a revived gene-therapy patent dispute with RegenxBio Inc. is drawing new attention to the question of when altered DNA becomes different enough from nature to be patented.Read More
DNA Patent Eligibility Under Spotlight in Sarepta’s En Banc Bid
